Dexcom Partners with Verily to Develop Second Generation CGM System

Continuous glucose monitoring (CGM) system monitors level of glucose in blood of diabetic patients. Wireless radio frequencies are used to provide information regarding glucose levels to monitoring device. Technological innovations have driven Growth in CGM system market. New systems have eliminated the daily finger prick calibration tests and send alerts to users if the glucose level reaches specified limits. 

sugarBEAT by Nemaura Medical:
Nemaura Medical has received a European regulatory approval for its sugarBeat CGM device. Loughborough based manufacturer is providing a package of a disposable skin patch with a sensor that sticks over patch, and sugarBEAT app or a standalone reader. The product eliminates the need of finger stick calibration and sticks easily to arm, abdomen, or leg without causing pain to patient. A sensor sends reading after every five minutes and users can access it with sugarBEAT app in smartphone. The results can be shared with doctors, caretakers, or others. Neamura is planning to release this product by the end of 2016. 

Dexcom’s Partnership with Verily:
Dexcom, a leading CGM manufacturer is collaborating with Verily, a medical tech firm of Google’s parent company Alphabet to launch a miniaturized continuous glucose monitor in 2018. Furthermore, they are also planning to launch Band aid-sized glucose monitor in 2020 or 2021, which is disposable and cheaper product. Two companies teamed up in August 2015 in order to bring the tiny technology of Verily and regulatory knowledge & industry experience of Dexcom together. 

The pair is aiming for developing a CGM device that does not require daily finger stick calibration. They are also planning to manufacture a monitoring device for type-2 diabetic patients who particularly use insulin. Both of them are taking help of FDA to accomplish these goals. 

The CEO of Dexcom believes that the sales of their products would take off in 2018 as the company didn’t sale considerably in 2016 and not expecting to get in 2017. Kevin Sayer, President and CEO of Dexcom said, "The milestones are really two big ones. There's our first-generation product, which we're working on, but our second-generation product--which we're also working on with Verily, and the second--generation product we've shown pictures of. That's turning the CGM transmitter literally into a Band-Aid-sized electronics configuration that a patient can peel off and throw away, that'd be very cost effective and that's the end game here. That's what we're shooting for every day because we know that's what patients want."

Analysts studying the industry have revealed comprehensive information along with statistics about changing market trends in research reports. Recently, Allied Market Research has published a report titled, “Europe Continuous Glucose Monitoring Systems Market - Opportunities and Forecasts, 2014 - 2021.” As per the report, the Europe continuous glucose monitoring systems market is estimated to grow at a CAGR of 38% from 2015 to 2021 and expected to reach $351.7 million by 2021. The report provides an extensive analysis of current market trend, drivers & opportunities, competitive intelligence, and value chain analysis. Furthermore, the research highlights SWOT analysis of leading manufacturers, recent developments, and Porter’s five forces model.

 

Related Post